M&A Deal Summary

DMK Pharmaceuticals Acquires US Compounding

On March 29, 2016, DMK Pharmaceuticals acquired life science company US Compounding

Acquisition Highlights
  • This is DMK Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is DMK Pharmaceuticals’ 3rd transaction in the United States.
  • This is DMK Pharmaceuticals’ 1st transaction in Arizona.

M&A Deal Summary
Date 2016-03-29
Target US Compounding
Sector Life Science
Buyer(s) DMK Pharmaceuticals
Deal Type Add-on Acquisition

Target

US Compounding

Conway, Arizona, United States
US Compounding, Inc. is a manufacturer of customized medications based on physicians’ orders and individual patient needs for more than 7,000 accounts.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

DMK Pharmaceuticals

San Diego, California, United States
Category Company
Founded 2006
Sector Life Science
Employees11
Revenue 2M USD (2021)
DESCRIPTION

DMK Pharmaceuticals is a specialty biopharmaceutical company that provides high quality, low-cost solutions for patients, physicians, and healthcare organizations in the multi-billion dollar therapeutic areas of respiratory disease and allergies. DMK Pharmaceuticals was incorporated in 2006 and is based in San Diego, California.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Arizona) 1 of 1
Country (United States) 3 of 3
Year (2016) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-08-06 3M - Taper Dry Powder Inhaler

United States

3M Co. - Taper Dry Powder Inhaler is a developer of treatment for asthma and chronic obstructive pulmonary disease (COPD).

Buy -
Mergr

Product

Company

Legal